Joseph Obeng, MD
Internal Medicine · Fort Worth, TXNPI 1023075058
Payments from drug & device makers
Across 331 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$502
- Lilly USA, LLC$426
- Abbott$230
- Daiichi Sankyo Inc.$206
- AstraZeneca$203
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,39499%
- Education$311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 140 | $1,327 |
| Novo Nordisk | 36 | $502 |
| Lilly USA, LLC | 28 | $426 |
| Abbott | 12 | $230 |
| Daiichi Sankyo Inc. | 20 | $206 |
| AstraZeneca | 10 | $203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $203 |
| Sanofi-aventis U.S. LLC | 8 | $128 |
| Bayer | 7 | $126 |
| Novartis | 5 | $111 |
| Pfizer | 5 | $99 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| GSK | 3 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| Boehringer Ingelheim | 2 | $50 |
| Eisai Inc. | 2 | $47 |
| Merck | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Vivus LLC | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $34 |
| Amgen | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $27 |
| Nestle Healthcare Nutrition Inc. | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Evoke Pharma, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Globus Medical | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$4,425 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 236 | $308,426 |
| MounjaroTirzepatide | 152 | $191,784 |
| ZenpepLipase/Protease/Amylase | 17 | $63,226 |
| EntrestoSacubitril/Valsartan | 26 | $46,595 |
| EliquisApixaban | 43 | $41,935 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $34,277 |
| JardianceEmpagliflozin | 30 | $31,843 |
| LinzessLinaclotide | 22 | $25,244 |
| JanuviaSitagliptin Phosphate | 16 | $24,351 |
| TrulicityDulaglutide | 21 | $23,757 |
| XareltoRivaroxaban | 14 | $20,930 |
| Nurtec OdtRimegepant Sulfate | 12 | $20,197 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $14,078 |
| MovantikNaloxegol Oxalate | 21 | $11,257 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $502 | $308,426236 claims |
| Lilly USA, LLCMounjaro, Trulicity | $426 | $215,541173 claims |
| Aimmune Therapeutics, Inc.Zenpep | $57 | $63,22617 claims |
| PfizerEliquis, Nurtec Odt | $99 | $62,13355 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $58 | $49,29677 claims |
| NovartisEntresto | $111 | $46,59526 claims |
| MerckJanuvia, Belsomra | $41 | $34,07931 claims |
| Boehringer IngelheimJardiance | $50 | $31,84330 claims |
| AbbVieLinzess | $1,327 | $25,24422 claims |
| Johnson & JohnsonXarelto | $14 | $20,93014 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $203 | $20,73429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Fort Worth
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.